Literature DB >> 22750912

Impact of diabetes mellitus on patients with unprotected left main coronary artery lesion disease treated with either percutaneous coronary intervention or coronary-artery bypass grafting.

Yawei Luo1, Xianpeng Yu, Fang Chen, Xin Du, Jiqiang He, Yuechun Gao, Xiaoling Zhang, Yuchen Zhang, Xuejun Ren, Shuzheng Lv, Changsheng Ma.   

Abstract

OBJECTIVE: This study was conducted to evaluate the impact of diabetes on patients with unprotected left main coronary artery (LMCA) disease treated with either percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG).
BACKGROUND: The optimal coronary revascularization strategy in diabetic patients with unprotected LMCA disease remains uncertain.
METHODS: A total of 823 consecutive patients having unprotected LMCA disease, who received drug-eluting stent (DES) (n=331) implantation or underwent CABG (n=492), were retrospectively analyzed. We compared the effects of these two treatments on clinical outcomes [death, cardiac death, myocardial infarction (MI), stroke, target vessel revascularization, and the composite of death, MI, or stroke], according to the patients' diabetic status.
RESULTS: After multivariable adjustment, the risk of death [hazard ratio (HR): 1.096, 95% confidence interval (CI): 0.541-2.222; P=0.799] and that of the composite of death, MI, or stroke (HR: 0.769, 95% CI: 0.446-1.328; P=0.346) were similar in the DES and CABG groups. However, the rate of target vessel revascularization was significantly higher in the DES group (HR: 0.169, 95% CI: 0.079-0.358; P<0.001). Incidence of MI (HR: 1.314, 95% CI: 0.238-7.254; P=0.754) and that of the composite of death, MI, or stroke (HR: 1.497, 95% CI: 0.682-3.289; P=0.315) were similar between DES and CABG in the nondiabetic group; however, in the diabetic population incidence of the composite of death, MI, or stroke (HR: 0.31, 95% CI: 0.126-0.761; P=0.011) was significantly higher in the DES compared with the CABG group, driven mainly by the significantly higher rate of MI in the DES group (HR: 0.114, 95% CI: 0.022-0.593; P=0.01). Rate of repeat revascularization was higher with DES compared with CABG in both diabetic and nondiabetic groups.
CONCLUSION: There was a prognostic impact of diabetes mellitus on treatment effects in patients with unprotected LMCA lesions who underwent DES or CABG. For patients with unprotected LMCA lesions, PCI with DES was an acceptable alternative to CABG at risk for higher repeat revascularization in the nondiabetic cohort, whereas in the diabetic cohort PCI with DES was inferior to CABG in terms of both safety and efficacy.

Entities:  

Mesh:

Year:  2012        PMID: 22750912     DOI: 10.1097/MCA.0b013e3283564961

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  4 in total

Review 1.  Comparing the Clinical Outcomes Between Insulin-treated and Non-insulin-treated Patients With Type 2 Diabetes Mellitus After Coronary Artery Bypass Surgery: A Systematic Review and Meta-analysis.

Authors:  Krishna Munnee; Pravesh K Bundhun; Hongzhi Quan; Zhangui Tang
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

2.  Efficacy and safety of drug-eluting stenting compared with bypass grafting in diabetic patients with multivessel and/or left main coronary artery disease.

Authors:  Xiaojun Xin; Xiangming Wang; Xuesi Dong; Yuanming Fan; Wei Shao; Xiang Lu; Pingxi Xiao
Journal:  Sci Rep       Date:  2019-05-13       Impact factor: 4.379

3.  A case of left main coronary artery disease in an octogenarian treated surgically and complicated by myocardial infarction: decisions, techniques, rescue and final outcome.

Authors:  Antoine Kossaify; Gilles Grollier
Journal:  Clin Med Insights Case Rep       Date:  2013-04-10

4.  Clinical outcome comparison of percutaneous coronary intervention and bypass surgery in diabetic patients with coronary artery disease: a meta-analysis of randomized controlled trials and observational studies.

Authors:  ChuanNan Zhai; HongLiang Cong; Kai Hou; YueCheng Hu; JingXia Zhang; YingYi Zhang
Journal:  Diabetol Metab Syndr       Date:  2019-12-19       Impact factor: 3.320

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.